For the laboratory researcher, the two peptides remain interesting tools provided they are used for what they truly are: compounds research use only With a robust but asymmetrical preclinical literature (35 AJSM 2026 studies for BPC-157, muscle/cardiac base for TB-500), and extremely limited human data on both sides, maintaining this nuance helps avoid claims not supported by science and properly position the two peptides within a well-designed research protocol
The Pickart & Margolina (2018) review documented its effects on over 4,000 human genes, with particular significance for collagen I and III synthesis, anti-inflammatory pathways, and stem cell mobilisation
The promise is real, but clinical readiness is not: Preclinical and early human data are compelling, but without large-scale trials, validated delivery methods, and long-term safety data, Epitalon remains an experimental peptide, one to watch closely, but not yet ready for mainstream clinical adoption
Factors That Affect Results Even in controlled animal studies, BPC-157 outcomes vary based on several factors
